CN104546770A - Azilsartan orally-disintegrating tablet and preparation method thereof - Google Patents
Azilsartan orally-disintegrating tablet and preparation method thereof Download PDFInfo
- Publication number
- CN104546770A CN104546770A CN201510005718.4A CN201510005718A CN104546770A CN 104546770 A CN104546770 A CN 104546770A CN 201510005718 A CN201510005718 A CN 201510005718A CN 104546770 A CN104546770 A CN 104546770A
- Authority
- CN
- China
- Prior art keywords
- azilsartan
- oral cavity
- cavity disintegration
- disintegration tablet
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and relates to an azilsartan orally-disintegrating tablet and a preparation method thereof. The orally-disintegrating tablet is prepared from azilsartan, a filling agent, an adhesive, a disintegrating agent, a lubricating agent and other pharmaceutically acceptable medical accessories. When in taking, the orally-disintegrating tablet can be put into the mouth and quickly dissolved or disintegrated into fine particles without the feel of gravels and then reaches the absorbing position along through saliva, and no water is needed. The azilsartan orally-disintegrating tablet has the characteristics of being fast to absorb, high in bioavailability, and convenient to take, and can be used for improving the medication compliance of a patient.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, be specifically related to a kind of active component be Azilsartan can the oral disintegrated preparation and preparation method thereof of disintegrate rapidly.
Background technology
Azilsartan (English name Azilsartan) is a kind of medicine being used for the treatment of vascular hypertension, its mechanism of action mainly blocks angiotensinⅡ by the combination of selective exclusion angiotensinⅡ and vascular smooth muscle AT1 receptor, reaches vasoconstrictive effect.Azilsartan is current uniquely a kind of Angiotensin Ⅱ receptor antagonist (husky smooth class) medicine being in late-stage clinical.This medicine in 2012 by the list marketing of Japanese Takeda Pharmaceutical Company Limited.Current Azilsartan goes on the market abroad and only has ordinary tablet; Domesticly there is no listing kind.
Although the incidence trend of vascular hypertension is tending towards rejuvenation at present, but depressor is mainly also aimed at gerontal patient, decline for some physiology especially and decline with masticatory ability or the elderly patient of nocturia, the taking of conventional tablet is often taken medicine the problems such as difficulty or nocturia increase.And true in the burst hyperpietic needing whenever and wherever possible to take medicine, exploitation takes the oral cavity disintegration tablet of Shi Buxu water delivery service for market is required.
Azilsartan is in white or yellow-white crystalline powder, and be insoluble drug, its dissolubility in water is less than 9 μm/ml.Structural formula is as follows:
。
Chinese patent CN201410188656 discloses particle diameter≤15 μm that a kind of pharmaceutical preparation improving Azilsartan stripping is characterized in that controlling Azilsartan, and adopts dry method direct compression method to prepare.CN102793680A discloses a kind of method that Azilsartan and pharmaceutically acceptable carrier material prepare azilsartan solid dispersion and pharmaceutical composition thereof.
Above patent, only studies, not for patient provides a kind of taking convenience, complies with and rapid-action pharmaceutical preparation from the dissolution aspect improving medicine.
Summary of the invention
The invention provides a kind of oral cavity disintegration tablet containing Azilsartan.Carry out the preparation of Azilsartan oral cavity disintegration tablet after adopting Azilsartan and hydrophilic filler to carry out micronization again, be intended to improve its disintegrative and dissolution, and the Compliance of patient can be improved.
The invention provides a kind of preparation method containing Azilsartan oral cavity disintegration tablet.
Oral cavity disintegration tablet provided by the invention, comprise common powder thing, disintegrating agent, the lubricant of Azilsartan and hydrophilic filler, its weight consists of Azilsartan 5.0% ~ 20.0%; Filler 30.0% ~ 85.0%; Disintegrating agent 5.0% ~ 25.0%; Lubricant 0.1% ~ 5.0%.
The common powder thing of Azilsartan of the present invention and filler, be carry out common powder by Azilsartan and the hydrophilic filler of one, its ratio is 1:1-1:5(w/w).
Oral cavity disintegration tablet of the present invention, its filler can be selected from one or more in mannitol, lactose, corn starch, pregelatinized Starch, wheaten starch, dextrin and microcrystalline Cellulose, and consumption is 30.0% ~ 85.0% of gross weight.
Oral cavity disintegration tablet of the present invention, disintegrating agent comprises one or more in cross-linking sodium carboxymethyl cellulose (CCNa), carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), crospolyvinylpyrrolidone (PVPP), crosslinked carboxymethyl fecula sodium (CCMS-Na), and consumption is 5.0% ~ 25.0% of gross weight.
Oral cavity disintegration tablet of the present invention, lubricant one or more in Polyethylene Glycol, magnesium stearate, sodium stearyl fumarate, micropowder silica gel, Pulvis Talci optional.
Oral cavity disintegration tablet of the present invention, can also contain in adhesive, correctives one or both.Wherein adhesive comprises polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC) or its combination; Correctives is acesulfame potassium, Mentholum, aspartame or its combination.
The preparation method of oral cavity disintegration tablet of the present invention carries out pelletizing press sheet again after first being anticipated by medicine.
In preparation method of the present invention by the concrete operations of medical preconditioning be: the common powder thing of recipe quantity medicine and a certain amount of filler with remain filler in prescription and disintegrating agent mixes, add appropriate adhesive and make suitable soft material for degree, the material of above-mentioned moistening is sieved and granulates and fully drying in air dry oven, sieving for standby.
Oral cavity disintegration tablet prepared by the present invention can use conventional tablet pharmaceutical equipment to produce, and the tablet of preparation has suitable hardness, can use conventional aluminum-plastic blister formula packaging, transport and condition of storage all unrestricted.
Oral cavity disintegration tablet prepared by the present invention, dissolution rate is fast, rapid-action, accumulative dissolution rate is high, after disintegrate, granule can pass through 24 mesh sieves completely, does not need water and without the need to chewing, and namely disintegratable is complete in 60s for medicine, borrow swallowing act to enter stomach after medicine disintegration and play drug effect, greatly facilitate part dysphagia or critical patient medication in particular circumstances.
The present invention is by adopting the method for medical preconditioning and screening adjuvant, the modes such as adjustment auxiliary material proportion, reach and improve adjuvant drug loading, improve the object of principal agent mobility and minimizing supplementary product consumption, the present invention selects suitable binding agent, not affect the stripping of Azilsartan for standard.Prepare the oral cavity disintegration tablet that color and luster is homogeneous, outward appearance is good.
Oral cavity disintegration tablet mouthfeel prepared by the present invention is good, volume is little, the heavy hardness of sheet is suitable, preparation technology is simple, be applicable to industrialized great production.
Specific embodiment
Embodiment 1 Azilsartan oral cavity disintegration tablet (1000)
Azilsartan and mannitol powder thing (1:5) 100g altogether
Mannitol 8.4 g
Microcrystalline Cellulose 20g
Low-substituted hydroxypropyl cellulose 8g
Polyvinylpyrrolidone 0.6g
Acesulfame potassium 1.2g
Mentholum 1.2g
Sodium stearyl fumarate 0.6g
Method for making:
1, Azilsartan in prescription and mannitol are carried out micronization processes in prescription ratio.
2, by the Azilsartan of recipe quantity and mannitol, powder thing and prescription remain mannitol, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, polyvinylpyrrolidone mixture are even in a mixer altogether.
3, in said mixture, add the alcohol-water solution soft material of 30%, 30 mesh sieves are granulated.
4, moisture L.O.D (90 DEG C is dried to, 5min) < 3%, 30 mesh sieve granulate, conversion yield, the consumption of additional low-substituted hydroxypropyl cellulose, acesulfame potassium, Mentholum and sodium stearyl fumarate, mixes with above-mentioned band medicine particle simulation 3 D stereo mixing method.
5, measure granule content, calculate sheet weight, tabletting, control hardness 20-40N.
Embodiment 2 Azilsartan oral cavity disintegration tablet (1000)
Azilsartan and mannitol powder thing (1:5) 100g altogether
Mannitol 19 g
Microcrystalline Cellulose 10g
Crospolyvinylpyrrolidone 8g
Acesulfame potassium 1.2g
Mentholum 1.2g
Sodium stearyl fumarate 0.6g
Method for making:
1, Azilsartan in prescription and mannitol are carried out micronization processes in prescription ratio.
2, by the Azilsartan of recipe quantity and mannitol, powder thing and prescription remain mannitol, microcrystalline Cellulose, crospolyvinylpyrrolidone mixture are even in a mixer altogether.
3, in said mixture, add the alcohol-water solution soft material of 30%, 30 mesh sieves are granulated.
4, moisture L.O.D (90 DEG C is dried to, 5min) < 3%, 30 mesh sieve granulate, conversion yield, the consumption of additional crospolyvinylpyrrolidone, acesulfame potassium, Mentholum and sodium stearyl fumarate, mixes with above-mentioned band medicine particle simulation 3 D stereo and mixes.
5, measure granule content, calculate sheet weight, tabletting, control hardness 20-40N.
Embodiment 3 Azilsartan oral cavity disintegration tablet (1000)
Azilsartan and mannitol powder thing (1:3) 80g altogether
Lactose 18.4 g
Microcrystalline Cellulose 30g
Cross-linking sodium carboxymethyl cellulose 8g
Polyvinylpyrrolidone 0.6g
Acesulfame potassium 1.2g
Mentholum 1.2g
Pulvis Talci 0.6g
Method for making:
1, Azilsartan in prescription and mannitol are carried out micronization processes in prescription ratio.
2, by the Azilsartan of recipe quantity and mannitol altogether powder thing and lactose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, mixture is even in a mixer for polyvinylpyrrolidone.
3, in said mixture, add the alcohol-water solution soft material of 30%, 30 mesh sieves are granulated.
4, moisture L.O.D (90 DEG C is dried to, 5min) < 3%, 30 mesh sieve granulate, conversion yield, additional cross-linking sodium carboxymethyl cellulose, acesulfame potassium, Mentholum and talcous consumption, mix with above-mentioned band medicine particle simulation 3 D stereo and mix.
5, measure granule content, calculate sheet weight, tabletting, control hardness 20-40N.
Embodiment 4 Azilsartan oral cavity disintegration tablet (1000)
Azilsartan and mannitol powder thing (1:3) 80g altogether
Microcrystalline Cellulose 23.4g
Low-substituted hydroxypropyl cellulose 13g
Polyvinylpyrrolidone 0.6g
Acesulfame potassium 1.2g
Mentholum 1.2g
Magnesium stearate 0.6g
Method for making:
1, Azilsartan in prescription and mannitol are carried out micronization processes in prescription ratio.
2, by the Azilsartan of recipe quantity and mannitol altogether powder thing and microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, mixture is even in a mixer for polyvinylpyrrolidone.
3, in said mixture, add the alcohol-water solution soft material of 30%, 30 mesh sieves are granulated.
4, moisture L.O.D (90 DEG C is dried to, 5min) < 3%, 30 mesh sieve granulate, conversion yield, the consumption of additional low-substituted hydroxypropyl cellulose, acesulfame potassium, Mentholum and magnesium stearate, mixes with above-mentioned band medicine particle simulation 3 D stereo and mixes.
5, measure granule content, calculate sheet weight, tabletting, control hardness 20-40N.
Embodiment 5 Azilsartan oral cavity disintegration tablet (1000)
Azilsartan and mannitol powder thing (1:3) 80g altogether
Microcrystalline Cellulose 30g
Low-substituted hydroxypropyl cellulose 17g
Carboxymethyl starch sodium 10g
Acesulfame potassium 1.2g
Mentholum 1.2g
Magnesium stearate 0.6g
Method for making:
1, Azilsartan in prescription and mannitol are carried out micronization processes in prescription ratio.
2, by the Azilsartan of recipe quantity and mannitol altogether powder thing and microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, mixture is even in a mixer for carboxymethyl starch sodium.
3, in said mixture, add the alcohol-water solution soft material of 30%, 30 mesh sieves are granulated.
4, moisture L.O.D (90 DEG C is dried to, 5min) < 3%, 30 mesh sieve granulate, conversion yield, the consumption of additional low-substituted hydroxypropyl cellulose, acesulfame potassium, Mentholum and magnesium stearate, mixes with above-mentioned band medicine particle simulation 3 D stereo and mixes.
5, measure granule content, calculate sheet weight, tabletting, control hardness 20-40N.
Test example 1 Azilsartan static test is investigated
Get Azilsartan oral cavity disintegration tablet 1, put 10ml test tube (test tube internal diameter is 13mm), in vitro have 2ml water, water temperature is 37 DEG C, tablet disintegrate in 1 minute, is dispersed in water.Pour out and sieve, use water 2ml at every turn, rinse test tube and screen cloth at twice, can all by 24 eye mesh screens.Check 6 (n=6) as stated above, the results are shown in following table:
Can be found out by above result; According to the oral cavity disintegration tablet prepared by embodiment, static disintegration time is all within 30s, and disintegrate is very fast, reaches oral cavity disintegration preparation requirement disintegration.
Test example 2 crude drug and hydrophilicity condiment carry out common micronization processes, prepare sample by the method in embodiment and technique, detect the dissolution of Azilsartan during 15min.
Dissolution test is carried out according to Chinese Pharmacopoeia 2010 editions two annex " dissolution method " second methods.Testing conditions is: PH6.8 phosphate buffer (containing 0.5%SDS); Slurry rotating speed: 50rpm; Dissolution medium: 900ml.Stripping the results are shown in following table:
| The ratio of Azilsartan and hydrophilicity condiment | 1:0 | 1:1 | 1:2 | 1:3 | 1:4 | 1:5 |
| 15min dissolution % | 23 | 32 | 58 | 83 | 79 | 82 |
As can be seen from above stripping result: the ratio in by specification Azilsartan and hydrophilicity condiment are carried out co-micronised after, the dissolution of active component when 15min is significantly improved.The present invention and technique make the dissolution rate of Azilsartan significantly increase.
Test example 3 Azilsartan oral cavity disintegration tablet 15min Dissolution Rate Testing is investigated and is carried out dissolution test according to Chinese Pharmacopoeia 2010 editions two annex " dissolution method " second methods.Testing conditions is: PH6.8 phosphate buffer (containing 0.5%SDS); Slurry rotating speed: 50rpm; Dissolution medium: 900ml.Stripping the results are shown in following table:
| Embodiment | 1 | 2 | 3 | 3 | 5 |
| Average dissolution % | 87 | 89 | 85 | 89 | 90 |
As can be seen from above stripping result, according to the oral cavity disintegration tablet prepared by embodiment, its 15min dissolution is all greater than 85%, and stripping is better.
Test example 4 Azilsartan oral cavity disintegration tablet influence factor experiment investigation
According to the investigation project listed by stability experiment in Chinese Pharmacopoeia 2010 editions two annex " medicine stability experiment instruction principle ", factors influencing is carried out to Azilsartan oral cavity disintegration tablet of the present invention.
A collection of Azilsartan oral cavity disintegration tablet is prepared by commercially available back according to the method for the embodiment of the present invention 1, put intensity of illumination 4500Lx ± 500 Lx, high temperature 60 DEG C and high humidity 25 DEG C, RH92.5% ± 5% time is placed 10 days, detect the 5th day and sampling in the 10th day, the results are shown in following table:
Conclusion: this sample is through factors influencing, and indices is all qualified compared with 0 day, illustrates that the formulation and technology of Azilsartan oral cavity disintegration tablet of the present invention is stablized feasible.
Claims (9)
1. an Azilsartan oral cavity disintegration tablet, is characterized in that, common powder thing, disintegrating agent, lubricant containing Azilsartan and hydrophilic filler, and its weight consists of Azilsartan 5.0% ~ 20.0%; Filler 30.0% ~ 85.0%; Disintegrating agent 5.0% ~ 25.0%; Lubricant 0.1% ~ 5.0%.
2. the common powder thing of Azilsartan according to claim 1 and filler, it is characterized in that Azilsartan and the hydrophilic filler of one carry out common powder, its ratio is 1:1-1:5(w/w).
3. oral cavity disintegration tablet according to claim 1, is characterized in that one or more that hydrophilic filler comprises in mannitol, lactose, corn starch, pregelatinized Starch, wheaten starch, dextrin and microcrystalline Cellulose.
4. oral cavity disintegration tablet according to claim 1, is characterized in that disintegrating agent can from one or more in cross-linking sodium carboxymethyl cellulose (CCNa), carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (L-HPC), crospolyvinylpyrrolidone (PVPP), crosslinked carboxymethyl fecula sodium (CCMS-Na).
5. oral cavity disintegration tablet according to claim 1, is characterized in that lubricant comprises one or more compositions in Polyethylene Glycol, magnesium stearate, sodium stearyl fumarate, micropowder silica gel, Pulvis Talci.
6. oral cavity disintegration tablet according to claim 1, it is characterized in that containing in adhesive, correctives one or both.
7. oral cavity disintegration tablet according to claim 6, is characterized in that adhesive is polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC) or its combination; Correctives comprises acesulfame potassium, Mentholum, aspartame or its combination.
8. after first being anticipated by medicine, carry out pelletizing press sheet according to the preparation method of any described oral cavity disintegration tablet of claim 1-6.
9. Orally disintegrating piece preparation method according to claim 8, medical preconditioning be after recipe quantity medicine and a certain amount of filler are carried out common powder thing with remain filler in prescription and disintegrating agent mixes, add appropriate adhesive and make suitable soft material, the material of above-mentioned moistening is sieved and granulates and fully drying in air dry oven, sieving for standby.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510005718.4A CN104546770A (en) | 2015-01-07 | 2015-01-07 | Azilsartan orally-disintegrating tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510005718.4A CN104546770A (en) | 2015-01-07 | 2015-01-07 | Azilsartan orally-disintegrating tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104546770A true CN104546770A (en) | 2015-04-29 |
Family
ID=53064554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510005718.4A Pending CN104546770A (en) | 2015-01-07 | 2015-01-07 | Azilsartan orally-disintegrating tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104546770A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853379A (en) * | 2016-03-31 | 2016-08-17 | 北京万全德众医药生物技术有限公司 | Ramelteon dispersible tablet and preparation process thereof |
| CN105878197A (en) * | 2016-03-31 | 2016-08-24 | 北京万全德众医药生物技术有限公司 | Riociguat orally disintegrating tablet and preparation method thereof |
| CN106109430A (en) * | 2016-07-28 | 2016-11-16 | 北京万全德众医药生物技术有限公司 | A kind of dispersible tablet containing letrozole and preparation method thereof |
| CN106389361A (en) * | 2016-03-31 | 2017-02-15 | 北京万全德众医药生物技术有限公司 | Orally disintegrating tablet containing ramelteon and preparation method of orally disintegrating tablet |
| CN106880601A (en) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | A kind of oral disnitegration tablet containing teriflunomide and preparation method thereof |
| CN106880607A (en) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | A kind of oral disnitegration tablet containing Rui Gefeini and preparation method thereof |
| CN111643461A (en) * | 2019-03-04 | 2020-09-11 | 鲁南制药集团股份有限公司 | Tablet for treating hypertension and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1314422A2 (en) * | 2001-11-14 | 2003-05-28 | Scg, Inc. | Orally disintegrating solid preparations and processes for the production thereof |
| CN101340896A (en) * | 2005-12-22 | 2009-01-07 | 特瓦制药工业有限公司 | Compressed solid dosage form containing low soluble medicament and preparation thereof |
| WO2010075347A2 (en) * | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
| CN101822674A (en) * | 2010-05-27 | 2010-09-08 | 北京德众万全医药科技有限公司 | Iloperidone drug composition and preparation method thereof |
| CN102793680A (en) * | 2011-05-23 | 2012-11-28 | 江苏恒瑞医药股份有限公司 | Azilsartan solid dispersion and preparation method and medicinal composition thereof |
| CN102895205A (en) * | 2012-11-09 | 2013-01-30 | 重庆市力扬医药开发有限公司 | Rapidly-dissolved azilsartan pharmaceutical preparation |
| CN103933000A (en) * | 2014-05-06 | 2014-07-23 | 山东新时代药业有限公司 | Azilsartan tablet and preparation method thereof |
-
2015
- 2015-01-07 CN CN201510005718.4A patent/CN104546770A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1314422A2 (en) * | 2001-11-14 | 2003-05-28 | Scg, Inc. | Orally disintegrating solid preparations and processes for the production thereof |
| CN101340896A (en) * | 2005-12-22 | 2009-01-07 | 特瓦制药工业有限公司 | Compressed solid dosage form containing low soluble medicament and preparation thereof |
| WO2010075347A2 (en) * | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
| CN101822674A (en) * | 2010-05-27 | 2010-09-08 | 北京德众万全医药科技有限公司 | Iloperidone drug composition and preparation method thereof |
| CN102793680A (en) * | 2011-05-23 | 2012-11-28 | 江苏恒瑞医药股份有限公司 | Azilsartan solid dispersion and preparation method and medicinal composition thereof |
| CN102895205A (en) * | 2012-11-09 | 2013-01-30 | 重庆市力扬医药开发有限公司 | Rapidly-dissolved azilsartan pharmaceutical preparation |
| CN103933000A (en) * | 2014-05-06 | 2014-07-23 | 山东新时代药业有限公司 | Azilsartan tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李全林主编: "《新药物与研究（下）》", 31 December 2008, 中国医药科技出版社 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106880601A (en) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | A kind of oral disnitegration tablet containing teriflunomide and preparation method thereof |
| CN106880607A (en) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | A kind of oral disnitegration tablet containing Rui Gefeini and preparation method thereof |
| CN105853379A (en) * | 2016-03-31 | 2016-08-17 | 北京万全德众医药生物技术有限公司 | Ramelteon dispersible tablet and preparation process thereof |
| CN105878197A (en) * | 2016-03-31 | 2016-08-24 | 北京万全德众医药生物技术有限公司 | Riociguat orally disintegrating tablet and preparation method thereof |
| CN106389361A (en) * | 2016-03-31 | 2017-02-15 | 北京万全德众医药生物技术有限公司 | Orally disintegrating tablet containing ramelteon and preparation method of orally disintegrating tablet |
| CN106109430A (en) * | 2016-07-28 | 2016-11-16 | 北京万全德众医药生物技术有限公司 | A kind of dispersible tablet containing letrozole and preparation method thereof |
| CN111643461A (en) * | 2019-03-04 | 2020-09-11 | 鲁南制药集团股份有限公司 | Tablet for treating hypertension and preparation method thereof |
| CN111643461B (en) * | 2019-03-04 | 2022-09-13 | 鲁南制药集团股份有限公司 | Tablet for treating hypertension and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104546770A (en) | Azilsartan orally-disintegrating tablet and preparation method thereof | |
| ES2626838T3 (en) | Pharmaceutical composition containing a tetrahydrofolic acid | |
| JP6151727B2 (en) | Ulipristal acetate ester tablets | |
| EP2939662B1 (en) | Pharmaceutical composition comprising temozolomide with improved stability and process for manufacturing the same | |
| KR102341165B1 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| EP3120871B1 (en) | Solid dispersion | |
| KR102684756B1 (en) | Pharmaceutical composition for oral administration containing enzalutamide | |
| CN104902928B (en) | Include the total micronizing product of uliprista acetate | |
| CN102764264A (en) | Celecoxib solid composition with high dissolution, preparation method and application | |
| CN104398481A (en) | Bilastine orally disintegrating tablet and preparing method thereof | |
| WO2019151405A1 (en) | Tablets and method for producing same | |
| CN104940152B (en) | A kind of pharmaceutical composition containing butanedioic acid Solifenacin | |
| JP2018065776A (en) | Pharmaceutical composition particle and orally disintegrable preparation containing the same, and method for producing pharmaceutical composition particle | |
| CN103083326A (en) | Ulipristal acetate medicine composition | |
| CN109481437B (en) | Losartan potassium pharmaceutical preparation | |
| CN106038502A (en) | Ramelteon oral disintegrating tablets and preparation method thereof | |
| CN103007286A (en) | Solid medicine composition of tolvaptan | |
| WO2017146053A1 (en) | Pharmaceutical composition particles and orally disintegrating preparation including same | |
| CN115177595A (en) | Oxagolide sodium tablet and preparation method thereof | |
| WO2017146052A1 (en) | Pharmaceutical composition particles, orally disintegrating preparation including same, and method for producing pharmaceutical composition particles | |
| JP6336078B2 (en) | Pharmaceutical composition | |
| WO2017093890A1 (en) | Clobazam tablet formulation and process for its preparation | |
| CN111544412B (en) | Cefixime composition and preparation method thereof | |
| JP2019089758A (en) | Method for improving dissolution in celecoxib-containing tablets | |
| WO2022042646A1 (en) | Lurasidone hydrochloride composition and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150429 |
|
| RJ01 | Rejection of invention patent application after publication |